Clinical trial · Observational
Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma
A Single-center Study of the Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma
NCT05759858CI-TRIAL-00064546unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the key genes of human and mouse hepatocellular carcinoma, identify the key genes and prognostic markers, and develop small molecule drugs targeting the key genes to treat hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| None of intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with hepatocellular carcinoma confirmed by pathology.
- description
- Patients with hepatocellular carcinoma confirmed by pathology.
- interventionNames
- Other: None of intervention
Primary outcomes (3)
- measure
- Key gene differences in hepatocellular carcinoma
- timeFrame
- Through study completion, an average of 1 year.
- description
- Key gene differences in hepatocellular carcinoma explored by RNA-seq.
- measure
- Overall survival
- timeFrame
- Through study completion, up to 5 years.
- description
- The time from the beginning of treatment to death (for any reason).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Hepatocellular carcinoma confirmed by pathology; 2. The patient has no combined organic diseases of heart, lung, and kidney, etc; 3. No history of chemotherapy, radiotherapy, upper abdominal surgery, or combined with other tumors; 4. The patient has successfully completed the operation and has complete clinical information and pathological data. Exclusion Criteria: 1. Patients who have previous history of other tumors or have undergone upper abdominal surgery; 2. Patients with multiple lesions and distant metastasis; 3. Patients who are complicated with organic diseases of important organs such as heart, lung and kidney and cannot tolerate surgery； 4. Patients who are more than 75 years old or less than 18 years old.
References
Publications (0)
Data not yet available
No reference posted for this study.